Boditech Med partners with Brazil's Biosys for local diagnostics production
Predicted impact: Low
Local diagnostics partnership in Brazil; no contract value given, small relative to market value.
Boditech Med바디텍메드
206640 · KOSDAQ · ₩206640 · 바디텍메드
₩8,500▼ ₩60 (0.70%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −38.67%
- Market cap
- ₩186B
- Enterprise value
- ₩164B
- P/E
- 7.2×
- P/B
- 0.8×
- Dividend yield
- 0.0%
- ROE
- 10.5%
- Net margin
- 14.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−39.9% from the high
₩8,350Today: ₩8,390 – ₩8,710₩14,150
Returns
- 1W−4.7%
- 1M−10.9%
- 3M−22.4%
- 6M−27.8%
- YTD−35.2%
- 1Y−38.7%
- Volume today
- 44,597
- 1.7× the 20-day average
- Traded today
- ₩379M
- Listed shares
- 21,907,921
- EPS (12 months)
- ₩1,185
- Earnings yield 13.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 55 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Partnership to expand local production in Brazil is seen as a positive step. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-9.1% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Boditech Med stock overview
Boditech Med (바디텍메드, KRX: 206640) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops, manufactures, and sells immunodiagnostic products used for point-of-care testing, organized into two business segments: immunodiagnostic cartridges (consumables for disease tests such as CRP, PCT, D-Dimer, and Vitamin D) and immunodiagnostic instruments (such as the ichroma and AFIAS series analyzers that run those cartridges). Its shares closed at ₩8,500 on Oct 28, 2026, down 0.70% on the day, giving it a market value of ₩186B.
Key facts
- Market cap
- ₩186B
- Sector
- Biotech & Pharma
- Latest price change
- −0.70%
- As of
- Oct 28, 2026
- Main business
- The company develops, manufactures, and sells immunodiagnostic products used for point-of-care testing, organized into two business segments: immunodiagnostic cartridges (consumables for disease tests such as CRP, PCT, D-Dimer, and Vitamin D) and immunodiagnostic instruments (such as the ichroma and AFIAS series analyzers that run those cartridges).
Quick answers about Boditech Med
- What does Boditech Med do?
- The company develops, manufactures, and sells immunodiagnostic products used for point-of-care testing, organized into two business segments: immunodiagnostic cartridges (consumables for disease tests such as CRP, PCT, D-Dimer, and Vitamin D) and immunodiagnostic instruments (such as the ichroma and AFIAS series analyzers that run those cartridges). Its cartridges cover infectious, diabetes, cardiovascular, cancer, and hormone-related conditions and are sold in more than 130 countries, with most revenue coming from exports.
- What is the market cap of Boditech Med?
- The market capitalisation of Boditech Med was ₩186B at the close on Oct 28, 2026.
- Who are the largest shareholders of Boditech Med?
- According to the latest official filings, the largest reported holders are Choi Ui-yeol (24.24%, as of Apr 7, 2026); Choi Kyu-ri (5.48%, as of Apr 7, 2026); National Pension Service (2.91%, as of Dec 31, 2025).
- When is the next earnings report from Boditech Med?
- Korean companies rarely announce results dates in advance. Based on when Boditech Med filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Boditech Med?
- Yes. The National Pension Service held 2.91% of Boditech Med shares as of Dec 31, 2025.
Company profile
The company develops, manufactures, and sells immunodiagnostic products used for point-of-care testing, organized into two business segments: immunodiagnostic cartridges (consumables for disease tests such as CRP, PCT, D-Dimer, and Vitamin D) and immunodiagnostic instruments (such as the ichroma and AFIAS series analyzers that run those cartridges). Its cartridges cover infectious, diabetes, cardiovascular, cancer, and hormone-related conditions and are sold in more than 130 countries, with most revenue coming from exports.
Written by AI from the company's latest annual report.
- Korean name
- 바디텍메드
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 최의열
- Founded
- Sep 2014
- Listed
- Dec 2014
- Listed shares
- 21,907,921
- Fiscal year ends
- Month 12
- Website
- www.boditech.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Boditech Med to boost price competitiveness with local production in Brazil
Predicted impact: Low
Local Brazil production plan is a small operational update with no stated size.
Recent filings
See all- Share cancellation decisionSep 22, 2026
- Trust Contract Termination Result ReportSep 22, 2026
- Material Matters Report (Decision on Termination of Trust Agreement for Own Share Acquisition)Sep 22, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earnings (consolidated)Jul 30, 2026
Titles in Korean until English translations are added.
Also known as: Boditech Med / 바디텍메드 / 206640 / KRX:206640
Source: KRX statistical information